Ca Nbridge Pharmaceuticals
Pharmaceuticals, 139 Main St Ste 100, Burlington, Massachusetts, 02142, United States, 201-500 Employees
Who is CANBRIDGE PHARMACEUTICALS
CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targete...
Read More
-
Headquarters: 139 Main St Ste 100, Burlington, Massachusetts, 02142, United States
-
Date Founded: 2012
-
Employees: 201-500
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 28
|
NAICS Code: 32 |
Show More
Does something look wrong? Fix it. | View contact records from CANBRIDGE PHARMACEUTICALS
CANbridge Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CANbridge Pharmaceuticals
Answer: CANbridge Pharmaceuticals's headquarters are located at 139 Main St Ste 100, Burlington, Massachusetts, 02142, United States
Answer: CANbridge Pharmaceuticals's official website is https://canbridgepharma.com
Answer: CANbridge Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: CANbridge Pharmaceuticals's SIC: 28
Answer: CANbridge Pharmaceuticals's NAICS: 32
Answer: CANbridge Pharmaceuticals has 201-500 employees
Answer: CANbridge Pharmaceuticals is in Pharmaceuticals
Answer: CANbridge Pharmaceuticals contact info: Phone number: Website: https://canbridgepharma.com
Answer: CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnologys NERLYNX (neratinib), in greater China, as well as rights to other novel candidates.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month